Mast Cell Tumor Grading and Prognosis in Dogs: Understanding the

The Most Common Malignant Skin Tumor

Mast cell tumors (MCTs) account for 16-21% of all cutaneous tumors in dogs, making them the most common malignant skin neoplasm. They present as raised, often erythematous skin masses that may be solitary or multiple. Their behavior is famously unpredictable — some remain localized and are cured by surgical excision alone, while others metastasize rapidly to regional lymph nodes, liver, spleen, and bone marrow despite aggressive treatment.

This behavioral heterogeneity makes histological grading the single most important prognostic tool. Without grading, treatment decisions are essentially blind.

The Two Grading Systems

Patnaik System (3-Tier, 1984)

Patnaik et al. (1984) established the original grading system that dominated veterinary oncology for nearly three decades:

• Grade I (well-differentiated): Mature mast cells with regular morphology, clear cytoplasmic granules, rare mitotic figures. Confined to dermis. Cure rate with adequate surgical excision exceeds 90%. Median survival: more than 5 years.
• Grade II (intermediately differentiated): Moderate cellular pleomorphism, variable granularity, occasional mitoses. May extend into subcutis. This is the most common grade (40-60% of MCTs) and the most prognostically ambiguous. Median survival: highly variable (1-5+ years depending on additional factors).
• Grade III (poorly differentiated): High cellular pleomorphism, sparse granulation, frequent mitotic figures, tissue invasion. High metastatic rate (55-96%). Median survival: 3-6 months with surgery alone.

The Patnaik system’s primary weakness is the Grade II category, which encompasses tumors with dramatically different biological behavior. A Grade II MCT might behave like a Grade I (cured by surgery) or like a Grade III (rapidly metastatic). This ambiguity frustrates treatment planning.

Kiupel System (2-Tier, 2011)

Kiupel et al. (2011) proposed a simplified system specifically to address Grade II ambiguity:

• Low-grade: Fewer than 7 mitotic figures per 10 high-power fields, no multinucleated cells (3 or more nuclei), no bizarre nuclei, no karyomegaly. These tumors have low metastatic potential and favorable prognosis.
• High-grade: Any one of the following — 7 or more mitotic figures per 10 HPF, presence of multinucleated cells, bizarre nuclei, or karyomegaly. These tumors have high metastatic potential and poor prognosis.

The Kiupel system has higher inter-pathologist agreement and better separation between favorable and unfavorable outcomes. Many pathology laboratories now report both Patnaik and Kiupel grades.

Beyond Grading: Additional Prognostic Factors

Mitotic Index

The number of mitotic figures per 10 high-power fields (MI) is independently prognostic regardless of grade. An MI of 5 or greater is associated with significantly shorter survival. This parameter helps stratify the problematic Patnaik Grade II tumors.

c-KIT Mutation Status

KIT is a receptor tyrosine kinase that drives mast cell proliferation. Internal tandem duplications (ITDs) in exons 8 and 11 of the c-KIT gene are found in approximately 15-30% of MCTs and correlate with higher grade, increased recurrence, and shorter survival.

c-KIT mutation status is clinically actionable because it predicts response to tyrosine kinase inhibitors (TKIs). London et al. (2009) demonstrated that toceranib phosphate (Palladia) — the first FDA-approved anti-cancer drug for dogs — produced objective response rates of approximately 37% in dogs with recurrent MCTs, with higher response rates in tumors harboring c-KIT mutations.

Sledge et al. (2016) further characterized c-KIT expression patterns and their correlation with tumor behavior, reinforcing mutation testing as a standard component of MCT workup.

Location

MCTs in certain anatomical locations carry worse prognosis regardless of grade:

• Mucocutaneous junctions (lip, prepuce, perineum): Higher metastatic rate
• Inguinal region: Higher recurrence rate
• Subcutaneous (vs. dermal): Generally more favorable than dermal tumors of equivalent grade
• Visceral: Poor prognosis regardless of other factors

Breed Predisposition

Certain breeds are predisposed to MCTs:

• Boxers: High incidence but tend toward lower-grade tumors with better prognosis
• Pugs: Predisposed but often develop multiple low-grade tumors
• Boston Terriers: Higher incidence
• Labrador Retrievers: Moderate predisposition
• Golden Retrievers: Moderate predisposition
• Shar Peis: High incidence, often aggressive behavior

Boxers and Pugs represent an important exception to the general MCT prognosis: despite high tumor incidence, their MCTs disproportionately skew toward well-differentiated, low-grade tumors with favorable outcomes.

Treatment Implications by Grade/Stage

Low-Grade (Kiupel) / Grade I (Patnaik)

• Wide surgical excision (2-3 cm lateral margins, one fascial plane deep) is generally curative
• Regional lymph node aspiration recommended to confirm absence of metastasis
• Adjuvant chemotherapy or radiation typically not required
• Recurrence rate with adequate margins is less than 10%
• Long-term prognosis: excellent

Intermediate Risk (Patnaik Grade II with Low Kiupel Grade)

• Wide surgical excision with clean margin confirmation via histopathology
• Regional lymph node staging (aspiration cytology and/or biopsy)
• Mitotic index and c-KIT mutation testing guide adjuvant therapy decisions
• Adjuvant radiation if margins are narrow or incomplete
• Consider adjuvant TKI (toceranib) or vinblastine/prednisone if high MI or c-KIT positive

High-Grade (Kiupel) / Grade III (Patnaik)

• Wide surgical excision plus regional lymph node excision
• Full staging (abdominal ultrasound, liver/spleen aspiration, buffy coat evaluation)
• Adjuvant chemotherapy: vinblastine/prednisone or CCNU (lomustine)
• TKI therapy (toceranib) if c-KIT mutation positive
• Radiation for incompletely excised tumors
• Prognosis: guarded; median survival 3-12 months depending on stage and treatment response

Practical Guidance for Owners

When a mast cell tumor is diagnosed:

1. Do not delay surgical excision — pre-surgical biopsy (fine needle aspirate) confirms MCT diagnosis, and definitive excision with wide margins should be planned promptly
2. Request both Patnaik and Kiupel grading on the histopathology report
3. Request mitotic index if not automatically reported
4. Consider c-KIT mutation testing for Grade II or high-grade tumors
5. Stage the disease: Regional lymph node aspiration at minimum; abdominal ultrasound for intermediate and high-grade tumors
6. Consult a veterinary oncologist for any tumor graded Patnaik Grade II with high MI, Patnaik Grade III, or Kiupel high-grade
7. Monitor for new tumors: Dogs that develop one MCT have increased risk of developing additional MCTs, particularly in predisposed breeds

Limitations

• Histological grading is subjective and inter-pathologist variability exists, particularly for Patnaik Grade II
• The Kiupel system improves but does not eliminate prognostic uncertainty
• c-KIT mutation testing is not universally available and adds cost
• Optimal surgical margins remain debated (2 cm vs. 3 cm lateral)
• Prognostic data comes primarily from referral hospital populations, which may not represent community practice outcomes

Related Conditions

• Mast Cell Tumor
• Cancer
• Skin Cancer

Related Science

• Cancer Screening in Dogs: What Helps
• Canine Cancer Immunotherapy Advances
• Monoclonal Antibody Therapy for Dogs

Frequently Asked Questions

My dog has a Patnaik Grade II mast cell tumor — what does that mean?

Grade II is the most common and most prognostically variable MCT grade. Ask your veterinarian for the Kiupel grade (low vs. high), mitotic index, and c-KIT mutation status — these additional parameters help stratify Grade II tumors into favorable and unfavorable categories.

Are mast cell tumors always cancerous?

All MCTs are neoplastic, but their behavior ranges from very low-grade (effectively benign after excision) to highly aggressive. Grade determines whether a specific MCT will behave in a clinically benign or malignant fashion.

Can mast cell tumors be prevented?

No known prevention strategy exists. Maintaining normal body weight and minimizing environmental carcinogen exposure are general cancer risk reduction strategies, but their specific impact on MCT development is unproven.

How do I check my dog for new mast cell tumors?

Monthly skin examinations — running your hands over the entire body and noting any new lumps or bumps — enable early detection of new MCTs. Any new skin mass in a dog with MCT history should be aspirated (fine needle aspirate) within 1-2 weeks of discovery.

Bottom Line

Mast cell tumor grading — using the Kiupel 2-tier system supplemented by mitotic index and c-KIT mutation testing — provides the most reliable prognostic and treatment-guiding information. The critical takeaway for owners: not all mast cell tumors are equal, and grading determines whether your dog needs surgery alone or surgery plus chemotherapy.

References

• Patnaik AK et al. Canine cutaneous mast cell tumor: grading and survival. Vet Pathol. 1984;21(5):469-474.
• Kiupel M et al. 2-tier grading system for canine MCTs. Vet Pathol. 2011;48(1):147-155.
• London CA et al. Toceranib phosphate for recurrent MCTs. Clin Cancer Res. 2009;15(11):3856-3865.
• Sledge DG et al. c-KIT expression in canine and human MCTs. Vet Pathol. 2016.